CytoSorbents Corporation (CTSO)

[techxen]

Ex vivo lung perfusion

Cytosorbents partnered with their distributor Aferetica in Italy back in 2017 to develop their Perlife system which is used for ex-vivo organ perfusion using Cytosorb's adsorption technologies to cleanse and recondition harvested solid organs such as the kidneys, livers and other internal organs: https://www.aferetica.com/en/therapeutical-solutions/perlife-tm/

Aferetica also developed PerLungs which is used for ex vivo reconditioning of donor lungs prior to transplantation : https://www.aferetica.com/en/therapeutical-solutions/perlungs/

In this month's Journal of Thoracic and Cardiovascular Surgery they published a study of ex vivo lung perfusion (EVLP) using Cytosorb, applied to donor lungs outside of the body before transplantation that improves organ quality and makes lungs that were previously unsuitable safe for transplant.
https://www.sciencedirect.com/science/article/abs/pii/S0022522320304724

This study doesn't mention specifically the Aferetica kit but nonetheless its good to see that the device is getting more published studies about the device use in this area. Lung transplantation is the only life–saving therapy for patients with certain types of end–stage lung disease; however the procedure has limited availability because not all donor lungs are safe for transplantation. This shortage of donor lungs results in the death of 20 percent of lung transplant candidates awaiting transplant.